Sionna Therapeutics to Participate in Upcoming September Investor Conferences
Rhea-AI Summary
Sionna Therapeutics (NASDAQ:SION), a clinical-stage biopharmaceutical company focused on developing treatments for cystic fibrosis, has announced its participation in two major healthcare investor conferences in September 2025.
The company will participate in fireside chats at the Cantor Global Healthcare Conference on September 3rd at 1:35 p.m. ET and the Morgan Stanley Global Healthcare Conference on September 8th at 7:00 a.m. ET. Both events will be held in New York and will be available via webcast on the company's investor relations website.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, SION declined 0.36%, reflecting a mild negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $4M from the company's valuation, bringing the market cap to $1.17B at that time.
Data tracked by StockTitan Argus on the day of publication.
WALTHAM, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that management will participate in fireside chats at the following upcoming investor events:
- Cantor Global Healthcare Conference 2025 in New York, NY on Wednesday, September 3rd, 2025, at 1:35 p.m. ET; and
- Morgan Stanley 23rd Annual Global Healthcare Conference in New York, NY on Monday, September 8th, 2025, at 7:00 a.m. ET.
Live webcasts of the presentations will be available under the “Events” page within the Investors section of Sionna’s website at https://investors.sionnatx.com/. Replays will also be available following the event.
About Sionna Therapeutics
Sionna Therapeutics is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for CF by developing novel medicines that normalize the function of the CFTR protein. Sionna’s goal is to deliver differentiated medicines for people living with CF that can restore their CFTR function to as close to normal as possible by directly stabilizing CFTR’s nucleotide binding domain 1 (NBD1), which Sionna believes is central to potentially unlocking dramatic improvements in clinical outcomes and quality of life for people with CF. Leveraging more than a decade of the co-founders’ research on NBD1, Sionna is advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, which resides in NBD1. Sionna is also developing a portfolio of complementary CFTR modulators that are designed to work synergistically with its NBD1 stabilizers to improve CFTR function. For more information about Sionna, visit www.sionnatx.com.
Sionna intends to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the Company’s Investor Relations website, in addition to following the Company’s press releases, SEC filings, public conference calls, presentations, and webcasts.
Media Contact
Adam Daley
CG Life
212.253.8881
adaley@cglife.com
Investor Contact
Juliet Labadorf
ir@sionnatx.com
FAQ
When is Sionna Therapeutics (SION) presenting at the Cantor Global Healthcare Conference 2025?
What time is Sionna Therapeutics' presentation at the Morgan Stanley Healthcare Conference 2025?
Where can I watch Sionna Therapeutics' (SION) investor conference presentations?
What is Sionna Therapeutics' (SION) main focus in drug development?
